Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Title: 

LOW DOSE ERYTHROMYCIN THERAPY FOR TREATMENT OF LUNG DISEASE DUE TO MUSTARD GAS

Type: SPEECH
Author(s): GHANIE M.,SHOHRATI M.,PANAHI U.,GHASEMZADEH M.
 
 
 
Name of Seminar: IRANIAN CONGRESS OF TOXICOLOGY
Type of Seminar:  CONGRESS
Sponsor:  SOCIETY OF TOXICOLOGY
Date:  2004Volume 8
 
 
Abstract: 

Currently base on documented information more of the casualty are suffering from long –term sequels of poisoning, mainly from mustard gas. Although some pulmonary disease such as Bronchiolitis, Chronic Bronchitis, Bronchiectsis and theracheal stenosis are being observed in these patients, but there are few information regarding pathophysiology of these problems. Currently treatment is Bronchodilators, corticostroids, mucolitics and antibiotics.
Chronic inflamation after mustard exposure is due to accumulation of nutrophils and lymphosytes. We have more reports about antiinflamatory effects of Erythromycine.
At this study on 43 casualtise we administered erythromycin at a daily dose of 400-600mg/day to 43 chemical esxposed subjects for 6 months. After 6 months erythromycin therapy, changes in symptom scale were assessed. We designed a questionnaire which included demographic information, Reports of spirometery data, drug consumption (regular, irregular), adverse side effects (diarrhea, nausea, and vomiting, abdominal pain) and any other clinical information that were asked. Breathlessness, cough and awakeness due to dyspnea both before and 6 months after erythromycin therapy according to standard scales were asked .All parts except of scale after treatment were completed. We conclude significant effects on cough, dyspnia, rate of hospitalization and need to Bronchodilators (P<0.05).

 
Keyword(s): 
 
 
Yearly Visit 45   tarjomyar
 
Latest on Blog
Enter SID Blog